Convatec announces the release of ConvaMax™
Convatec Group Plc (“Convatec”), a leading global medical technology company, announced January 14th 2020 the release of ConvaMax™ the NEW superabsorber dressing distributed by Convatec. The global superabsorber market is currently greater than $100m growing at +7% 1
ConvaMax™ superabsorber wound dressing is used for the management of highly exuding wounds, including leg ulcers, pressure ulcers, diabetic foot ulcers and dehisced surgical wounds.
ConvaMax™ superabsorber manages excess moisture to help protect skin integrity2. Where there is a real risk of skin damage due to high levels of exudate, ConvaMax™ is ideal. It is available in non-adhesive and silicone adhesive forms, providing complete flexibility to support your care protocol. This includes under compression bandaging or with an additional primary dressing.
At Convatec, we are committed to innovating our product pipeline providing both our customers and patients with further differentiated technologies and complete solutions for managing chronic and acute wounds.
David Shepherd, President of Convatec’s Advanced Wound Care Franchise, believes that: “ConvaMax™ will add to our already strong wound portfolio. ConvaMax™ gives us a great product for highly exuding wounds; the reception from our sales and marketing colleagues and the expert customers who have seen the dressings already has been extremely positive, and we look forward to a similar reaction as countries begin to launch the product in the coming months.”
Full year Sales 2018 Smartrak 2019
World Union of Wound Healing Societies (2019) Consensus Document. Wound exudate: effective assessment and management Wounds International. Available at: www.woundsinternational.com
For more information please call.
Analysts and Investors
Mark Reynolds, Director Investor Relations
+44 (0)7551 036625
Buchanan Charles Ryland/Chris Lane/Vicky Hayns
+44 (0)207 466 5000
Convatec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care.
Convatec announces the release of ConvaMax™Read more
Interim Results for the 6 months ended 30 June 2020Read more
Trading update for the three months ended 30 September 2020Read more
Expert panel publishes Wound Hygiene consensusRead more
Convatec Group Plc Annual Results 2019Read more
Trading update for the three months ended 31 March 2020Read more